COVID-19 Forum, Information, Studies, Treatments

COVID-19 Coronavirus => COVID-19 Later Stage Hospital Studies and Trials => Topic started by: admin on November 17, 2020, 08:46:03 AM

Title: New study by NIH claims Remdesivir reduces mortality and length of stay???
Post by: admin on November 17, 2020, 08:46:03 AM
After the giant long term WHO trial that came out (https://www.covid-19forum.org/index.php?topic=366.0) at about the same time, that confirmed that Remdesivir does not significantly reduce mortality and in this trial even suggested it does not reduce hospital stay, the NIH/Fauci pulled a fresh new rabbit out of their hat. Based on the abject lie it begins with, perhaps it should be taken with a shaker of salt:

"Abstract
Background
Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious."

That is a filthy lie. https://www.covid-19forum.org/index.php?board=3.0

https://www.nejm.org/doi/full/10.1056/NEJMoa2007764

"Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days."

So the 10 day course of treatment must run about $6400. Such a deal!

A big fat lie like that after destroying the reputation of 65-year old proven-safe hydroxychloroquine, through a fraudulent study that was larded with panel members that had financial interests or other ties to Gilead Sciences, while HCQ continues to be up to 99-100% effective with a $20 treatment protocol in the early outpatient setting.
https://www.covid-19forum.org/index.php?topic=5.0

added 5-2-21:  "PulmCrit – Eleven reasons the NEJM paper on remdesivir reveals nothing"
https://www.covid-19forum.org/index.php?topic=217.0